Daliresp (DA-li-resp), a new oral tablet for severe COPD in patients with chronic bronchitis
You'll hear about Daliresp (DA-li-resp), a new oral tablet for severe COPD in patients with chronic bronchitis.
Daliresp (roflumilast) is the first in a new class of oral phosphodiesterase 4 inhibitors. It works by reducing lung inflammation.
It's added to the usual bronchodilator therapy to decrease exacerbations...but only for severe, chronic COPD.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote